Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | $0.00 |
| Operating income | -$22.8M | -$62.7M |
| Net income | -$20.6M | -$57.6M |
| EPS (diluted) | -$5.15 | -$2.93 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$18.1M | -$54.2M |
| Capital expenditures | $109K | $95.0K |
| Free cash flow | -$18.2M | -$54.3M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $61.6M | $47.1M |
| Total assets | $77.5M | $117M |
| Total liabilities | $5.39M | $10.5M |
| Shareholders' equity | -$54.6M | $107M |
| Retained earnings | -$58.3M | -$116M |
| Shares (wtd avg diluted) | 4.00M | 19.6M |
Every figure is extracted from Aardvark Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.